

April 20, 2018

Chiyoda Awarded Engineering, Procurement, and Construction of a New Facility for Manufacturing Non-standard Peptide Therapeutics

Chiyoda Corporation (“Chiyoda”) (TSE: 6366; ISIN: JP352800004) is pleased to announce that it has reached an EPC (Engineering, Procurement and Construction) agreement with PeptiStar Inc. (Headquartered in Osaka) to construct its facility to manufacture non-standard peptide therapeutics.

1. Client: PeptiStar Inc.
2. Project Name: EPC Work for Manufacturing Plants No. 1 and No. 2
3. Construction Site: Settsu City, Osaka Prefecture
4. Completion: Mid 2019
5. Project Outline: The manufacturing facility to be constructed through this project is to carry out research and development, and to manufacture non-standard peptide therapeutics, one of the middle-molecule drugs whose market is growing these days. The facility utilizes related intellectual properties and technologies of PeptiDream Inc., and other elemental technologies to manufacture non-standard peptide therapeutics.

In addition to capital increase envisaged by the three existing shareholders, PeptiStar Inc. expects additional increase of capital from the companies which provide elemental technologies to the manufacturing facility. Chiyoda is one of the new investors. This award and investment are in alliance with one of the Chiyoda’s growth strategies in the medium-term management plan, “expansion of global environmental engineering business.”

Chiyoda is to contribute to “achieve the research and development of synthesis and manufacturing process of the peptide therapeutics as well as its production by gathering knowledge and know-how of all the Japanese partners,” which is the goal of the client.

- *1. PeptiStar Inc. had been established on August 7, 2017 by PeptiDream Inc., Shionogi & Co. Ltd., and Sekisui Chemical Co., Ltd. In addition to these three original members, several companies including Chiyoda are to be new shareholders.
- *2. Non-standard peptide therapeutics comprises of 20 amino acids, naturally occurring type, and non-natural amino acids, which contribute to increase varieties of compounds, and accordingly to increase possibility of drug discovery.

For more information, please contact:

Chiyoda Corporation

IR, PR & CSR Department

URL: <https://www.chiyodacorp.com/en/contact/index.php>